TABLE 3.
Rate of Completion of the 3-Dose HPV4 Vaccine Series Within 7 and 12 Months of Initiation of Vaccination (N = 3297)
| Characteristic | 7 mo |
12 mo |
||
|---|---|---|---|---|
| n (%) | Pa | n (%) | Pa | |
| Total | 471 (14.3) | — | 914 (27.7) | — |
| Age group, y | ||||
| 9–10 | 18 (12.9) | .01 | 30 (21.4) | <.001 |
| 11–12 | 55 (10.7) | — | 101 (19.6) | — |
| 13–18 | 361 (14.7) | — | 727 (29.6) | — |
| 19–26 | 37 (20.1) | — | 56 (30.4) | — |
| Race | ||||
| Black | 246 (11.1) | <.001 | 528 (23.8) | <.001 |
| White | 204 (21.7) | — | 349 (37.0) | — |
| Otherb | 21 (15.3) | — | 37 (27.0) | — |
| Insurance used at HPV4 dose 1 | ||||
| Private | 190 (18.9) | <.001 | 327 (32.5) | <.001 |
| Public | 269 (12.5) | — | 564 (26.3) | — |
| None | 8 (8.5) | — | 14 (14.9) | — |
| Pregnancy diagnosis | ||||
| Yes | 2 (4.9) | .1 | 5 (7.6) | <.001 |
| DMPA at HPV4 dose 1 | ||||
| Yes | 45 (13.0) | .47 | 104 (30.1) | .3 |
| DMPA any time | ||||
| Yes | 113 (17.5) | .009 | 274 (37.6) | <.001 |
| Clinic location of HPV4 dose 1 | ||||
| Pediatrics | 101 (11.8) | .015 | 197 (23.0) | .002 |
| Adolescent base | 334 (14.8) | — | 663 (29.5) | — |
| Adolescent satellite | 31 (20.9) | — | 46 (31.1) | — |
| Specialty clinics | 5 (12.2) | — | 8 (19.5) | — |
| Time period of vaccine series initiation | ||||
| November 2006—March 2007 | 85 (17.8) | <.001 | 162 (33.9) | .003 |
| April 2007—August 2007 | 169 (15.4) | — | 313 (28.6) | — |
| September 2007—January 2008 | 138 (14.7) | — | 243 (25.8) | — |
| February 2008—June 2008 | 79 (10.1) | — | 196 (25.1) | — |
The denominators used to calculate percentages are the number of female patients with the reported characteristic. DMPA indicates depot medroxyprogesterone acetate.
a
Derived from a χ2 test, with the exception of pregnancy, for which a Fisher's exact test was used.
b
Includes Asian, mixed race, American Indian, and other.